Low forms of cyclin E reduce breast cancer drug's effectiveness
Tuesday, February 9, 2010 - 14:14
in Health & Medicine
Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M. D. Anderson Cancer Center report in Clinical Cancer Research.
Read the whole article on Physorg
More from Physorg
Related
- Low forms of cyclin E reduce breast cancer drug's effectivenessTue, 9 Feb 2010, 13:58:50 EST
- False negative tests in breast cancer may lead to wrong drug choiceMon, 27 Jun 2011, 16:38:36 EDT
- Meta-analyses of global trials finds in favor of aromatase inhibitorsThu, 11 Dec 2008, 16:57:26 EST
- Anti-estrogen drug therapy reduces risk of invasive breast cancer in older womenTue, 10 Jun 2008, 21:49:44 EDT
- Overexpressed protein converts noninvasive breast cancer into invasive diseaseTue, 8 Sep 2009, 14:44:27 EDT